BACKGROUND: Nischarin (encoded by NISCH), an α5 integrin-binding protein, has been identified as a regulator of breast cancer cell invasion. We hypothesized that it might be a tumor suppressor and were interested in its regulation. METHODS: We examined nischarin expression in approximately 300 human breast cancer and normal tissues using quantitative polymerase chain reaction and immunohistochemistry. Loss of heterozygosity analysis was performed by examining three microsatellite markers located near the NISCH locus in normal and tumor tissues. We generated derivatives of MDA-MB-231 human metastatic breast cancer cells that overexpressed nischarin and measured tumor growth from these cells as xenografts in mice; metastasis by these cells after tail vein injection; and α5 integrin expression, Rac, and focal adhesion kinase (FAK) signaling using western blotting. We also generated clones of MCF-7 human breast cancer cells in which nischarin expression was silenced and measured tumor growth in mouse xenograft models (n = 5 for all mouse experiments). P values were from two-sided Student t tests in pairwise comparisons. RESULTS: Normal human breast tissue samples had statistically significantly higher expression of nischarin mRNA compared with tumor tissue samples (mean level in normal breast = 50.7 [arbitrary units], in breast tumor = 16.49 [arbitrary units], difference = 34.21, 95% confidence interval [CI] = 11.63 to 56.79, P = .003), and loss of heterozygosity was associated with loss of nischarin expression. MDA-MB-231 cells in which nischarin was overexpressed had statistically significantly reduced tumor growth and metastasis compared with parental MDA-MB-231 cells (mean volume at day 40, control vs nischarin-expressing tumors, 1977 vs 42.27 mm(3), difference = 1935 mm(3), 95% CI = 395 to 3475 mm(3), P = .025). Moreover, MCF-7 tumor xenografts in which nischarin expression was silenced grew statistically significantly faster than parental cells (mean volume at day 63, tumors with scrambled short hairpin RNA [shRNA] vs with nischarin shRNA, 224 vs 1262 mm(3), difference = 1038 mm(3), 95% CI = 899.6 to 1176 mm(3), P < .001). Overexpression of nischarin was associated with decreased α5 integrin expression, FAK phosphorylation, and Rac activation. CONCLUSION: Nischarin may be a novel tumor suppressor that limits breast cancer progression by regulating α5 integrin expression and subsequently α5 integrin-, FAK-, and Rac-mediated signaling.
BACKGROUND:Nischarin (encoded by NISCH), an α5 integrin-binding protein, has been identified as a regulator of breast cancer cell invasion. We hypothesized that it might be a tumor suppressor and were interested in its regulation. METHODS: We examined nischarin expression in approximately 300 humanbreast cancer and normal tissues using quantitative polymerase chain reaction and immunohistochemistry. Loss of heterozygosity analysis was performed by examining three microsatellite markers located near the NISCH locus in normal and tumor tissues. We generated derivatives of MDA-MB-231 human metastatic breast cancer cells that overexpressed nischarin and measured tumor growth from these cells as xenografts in mice; metastasis by these cells after tail vein injection; and α5 integrin expression, Rac, and focal adhesion kinase (FAK) signaling using western blotting. We also generated clones of MCF-7 humanbreast cancer cells in which nischarin expression was silenced and measured tumor growth in mouse xenograft models (n = 5 for all mouse experiments). P values were from two-sided Student t tests in pairwise comparisons. RESULTS: Normal human breast tissue samples had statistically significantly higher expression of nischarin mRNA compared with tumor tissue samples (mean level in normal breast = 50.7 [arbitrary units], in breast tumor = 16.49 [arbitrary units], difference = 34.21, 95% confidence interval [CI] = 11.63 to 56.79, P = .003), and loss of heterozygosity was associated with loss of nischarin expression. MDA-MB-231 cells in which nischarin was overexpressed had statistically significantly reduced tumor growth and metastasis compared with parental MDA-MB-231 cells (mean volume at day 40, control vs nischarin-expressing tumors, 1977 vs 42.27 mm(3), difference = 1935 mm(3), 95% CI = 395 to 3475 mm(3), P = .025). Moreover, MCF-7 tumor xenografts in which nischarin expression was silenced grew statistically significantly faster than parental cells (mean volume at day 63, tumors with scrambled short hairpin RNA [shRNA] vs with nischarin shRNA, 224 vs 1262 mm(3), difference = 1038 mm(3), 95% CI = 899.6 to 1176 mm(3), P < .001). Overexpression of nischarin was associated with decreased α5 integrin expression, FAK phosphorylation, and Rac activation. CONCLUSION:Nischarin may be a novel tumor suppressor that limits breast cancer progression by regulating α5 integrin expression and subsequently α5 integrin-, FAK-, and Rac-mediated signaling.
Authors: Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend Journal: Nature Date: 2002-01-31 Impact factor: 49.962
Authors: Xiao-Jun Ma; Zuncai Wang; Paula D Ryan; Steven J Isakoff; Anne Barmettler; Andrew Fuller; Beth Muir; Gayatry Mohapatra; Ranelle Salunga; J Todd Tuggle; Yen Tran; Diem Tran; Ana Tassin; Paul Amon; Wilson Wang; Wei Wang; Edward Enright; Kimberly Stecker; Eden Estepa-Sabal; Barbara Smith; Jerry Younger; Ulysses Balis; James Michaelson; Atul Bhan; Karleen Habin; Thomas M Baer; Joan Brugge; Daniel A Haber; Mark G Erlander; Dennis C Sgroi Journal: Cancer Cell Date: 2004-06 Impact factor: 31.743
Authors: Mazvita Maziveyi; Shengli Dong; Somesh Baranwal; Ali Mehrnezhad; Rajamani Rathinam; Thomas M Huckaba; Donald E Mercante; Kidong Park; Suresh K Alahari Journal: Cancer Res Date: 2019-01-11 Impact factor: 12.701
Authors: Lianjin Jin; Oliver Wessely; Eric G Marcusson; Cristina Ivan; George A Calin; Suresh K Alahari Journal: Cancer Res Date: 2013-01-21 Impact factor: 12.701
Authors: Kimberly Laskie Ostrow; Christina Michailidi; Rafael Guerrero-Preston; Mohammad O Hoque; Alissa Greenberg; William Rom; David Sidransky Journal: Epigenetics Date: 2013-03-15 Impact factor: 4.528
Authors: Maria Rusan; Kapsok Li; Yvonne Li; Camilla L Christensen; Brian J Abraham; Nicholas Kwiatkowski; Kevin A Buczkowski; Bruno Bockorny; Ting Chen; Shuai Li; Kevin Rhee; Haikuo Zhang; Wankun Chen; Hideki Terai; Tiffany Tavares; Alan L Leggett; Tianxia Li; Yichen Wang; Tinghu Zhang; Tae-Jung Kim; Sook-Hee Hong; Neermala Poudel-Neupane; Michael Silkes; Tenny Mudianto; Li Tan; Takeshi Shimamura; Matthew Meyerson; Adam J Bass; Hideo Watanabe; Nathanael S Gray; Richard A Young; Kwok-Kin Wong; Peter S Hammerman Journal: Cancer Discov Date: 2017-10-20 Impact factor: 39.397
Authors: Samuel C Okpechi; Hassan Yousefi; Khoa Nguyen; Thomas Cheng; Nikhilesh V Alahari; Bridgette Collins-Burow; Matthew E Burow; Suresh K Alahari Journal: Oncogene Date: 2022-01-22 Impact factor: 9.867